Next-generation COVID-19 vaccines: Opportunities for vaccine development and challenges in tackling COVID-19-Reference-Cited by-同舟云学术

Next-generation COVID-19 vaccines: Opportunities for vaccine development and challenges in tackling COVID-19

Published:2021-06-30 Issue:3 Volume:15 Page:118-123
ISSN:1881-7831
Container-title:Drug Discoveries & Therapeutics
language:en
Short-container-title:DD&T

Author:

Li Qian¹,Wang Jun²,Tang Yang¹,Lu Hongzhou¹

Affiliation:

1. Department of Infectious Diseases, Shanghai Public Health Clinical Center, Shanghai, China.

2. Center of Clinical Laboratory, The Fifth People’s Hospital of Wuxi, Jiangnan University, Wuxi, China.

Publisher

International Research and Cooperation Association for Bio & Socio-Sciences Advancement (IRCA-BSSA)

Subject

Pharmacology (medical),General Pharmacology, Toxicology and Pharmaceutics,General Medicine

Link

https://www.jstage.jst.go.jp/article/ddt/15/3/15_2021.01058/_pdf

Reference40 articles.

1. 1. World Health Organization. WHO Coronavirus (COVID-19) Dashboard. https://covid19.who.int/ (accessed June 25, 2021).

2. 2. Jun C, Hongzhou L. New challenges to fighting COVID-19: Virus variants, potential vaccines, and development of antivirals: The case of influenza viruses. Biosci Trends. 2021; 15:126-128.

3. 3. Ayouni I, Maatoug J, Dhouib W, Zammit N, Fredj SB, Ghammam R, Ghannem H. Effective public health measures to mitigate the spread of COVID-19: A systematic review. BMC Public Health. 2021;21(1):1015.

4. 4. World Health Organization. Tracking SARS-CoV-2 variants. https://www.who.int/en/activities/tracking-SARS-CoV-2-variants/ (accessed June 25, 2021).

5. 5. CTV News. B.1.617 variant first identified in India classified as variant of global concern. https://www.ctvnews.ca/health/coronavirus/b-1-617-variant-first-identified-in-india-classified-as-variant-of-global-concern-1.5421363 (accessed June 25, 2021).

Cited by 17 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Socio-demographic determinants of COVID-19 vaccine uptake in Ontario: Exploring differences across the Health Region model;Vaccine;2024-03

2. Designing a sustainable vaccine supply chain by considering demand substitution and value-added function during a pandemic outbreak;Computers & Industrial Engineering;2024-01

3. Clinical and immunological efficacy of intranasal interferon in the post-vaccination period in patients vaccinated against SARS-CoV-2 coronavirus;Russian Journal of Immunology;2023-09-22

4. An update on vaccine status and the role of nanomedicine against SARS‐CoV‐2: A narrative review;Health Science Reports;2023-07

5. Exosome-Based Multivalent Vaccine: Achieving Potent Immunization, Broadened Reactivity, and Strong T-Cell Responses with Nanograms of Proteins;Microbiology Spectrum;2023-06-15